vs
Side-by-side financial comparison of Commerce.com, Inc. (CMRC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $89.5M, roughly 2.0× Commerce.com, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -9.3%, a 11.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 2.9%). Over the past eight quarters, Commerce.com, Inc.'s revenue compounded faster (5.5% CAGR vs -0.2%).
SPS Commerce, Inc. is a technology and application software company based in the United States that provides cloud-based supply chain management software. The company's headquarters are located in Minneapolis, Minnesota, but it also has a US office in New Jersey, and international locations in Amsterdam, Beijing, Breukelen, Hong Kong, Kyiv, Melbourne, Montpellier, Sydney, and Toronto.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CMRC vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $89.5M | $177.4M |
| Net Profit | $-8.4M | $2.9M |
| Gross Margin | 78.3% | — |
| Operating Margin | -7.4% | 3.9% |
| Net Margin | -9.3% | 1.6% |
| Revenue YoY | 2.9% | 5.0% |
| Net Profit YoY | -250.0% | — |
| EPS (diluted) | $-0.11 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $89.5M | $196.9M | ||
| Q3 25 | $86.0M | $179.5M | ||
| Q2 25 | $84.4M | $181.1M | ||
| Q1 25 | $82.4M | $168.9M | ||
| Q4 24 | $87.0M | $187.3M | ||
| Q3 24 | $83.7M | $168.6M | ||
| Q2 24 | $81.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-8.4M | — | ||
| Q3 25 | $-2.2M | $5.4M | ||
| Q2 25 | $-8.4M | $-4.8M | ||
| Q1 25 | $-353.0K | $4.8M | ||
| Q4 24 | $-2.4M | — | ||
| Q3 24 | $-7.0M | $-143.5M | ||
| Q2 24 | $-11.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | 79.5% | ||
| Q3 25 | 78.4% | 80.9% | ||
| Q2 25 | 79.0% | 77.4% | ||
| Q1 25 | 79.4% | 79.7% | ||
| Q4 24 | 77.6% | 78.7% | ||
| Q3 24 | 76.3% | 76.9% | ||
| Q2 24 | 75.8% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -7.4% | 1.2% | ||
| Q3 25 | -0.5% | 3.5% | ||
| Q2 25 | -8.0% | 4.7% | ||
| Q1 25 | -2.9% | 1.2% | ||
| Q4 24 | -0.9% | 13.2% | ||
| Q3 24 | -23.0% | -82.8% | ||
| Q2 24 | -16.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -9.3% | — | ||
| Q3 25 | -2.6% | 3.0% | ||
| Q2 25 | -9.9% | -2.7% | ||
| Q1 25 | -0.4% | 2.8% | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | -8.4% | -85.1% | ||
| Q2 24 | -13.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.11 | $0.05 | ||
| Q3 25 | $-0.03 | $0.12 | ||
| Q2 25 | $-0.10 | $-0.11 | ||
| Q1 25 | $0.00 | $0.10 | ||
| Q4 24 | $-0.03 | $0.38 | ||
| Q3 24 | $-0.09 | $-3.11 | ||
| Q2 24 | $-0.15 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $141.1M | $144.3M |
| Total DebtLower is stronger | $157.0M | — |
| Stockholders' EquityBook value | $39.4M | $653.9M |
| Total Assets | $308.8M | $1.2B |
| Debt / EquityLower = less leverage | 3.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $141.1M | $238.4M | ||
| Q3 25 | $142.0M | $246.3M | ||
| Q2 25 | $134.5M | $445.9M | ||
| Q1 25 | $120.7M | $493.6M | ||
| Q4 24 | $178.2M | $484.6M | ||
| Q3 24 | $168.4M | $453.8M | ||
| Q2 24 | $275.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $157.0M | $372.2M | ||
| Q3 25 | $157.3M | $376.7M | ||
| Q2 25 | $157.5M | $580.5M | ||
| Q1 25 | $157.8M | $583.4M | ||
| Q4 24 | $216.5M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | $340.9M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $39.4M | $693.1M | ||
| Q3 25 | $42.8M | $727.2M | ||
| Q2 25 | $38.8M | $757.8M | ||
| Q1 25 | $38.1M | $798.5M | ||
| Q4 24 | $33.4M | $778.3M | ||
| Q3 24 | $29.0M | $749.6M | ||
| Q2 24 | $26.1M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $308.8M | $1.3B | ||
| Q3 25 | $309.5M | $1.3B | ||
| Q2 25 | $302.5M | $1.5B | ||
| Q1 25 | $286.3M | $1.6B | ||
| Q4 24 | $340.3M | $1.6B | ||
| Q3 24 | $335.1M | $1.5B | ||
| Q2 24 | $452.5M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 3.99× | 0.54× | ||
| Q3 25 | 3.67× | 0.52× | ||
| Q2 25 | 4.06× | 0.77× | ||
| Q1 25 | 4.14× | 0.73× | ||
| Q4 24 | 6.49× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | 13.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $980.0K | — |
| Free Cash FlowOCF − Capex | $-2.2M | — |
| FCF MarginFCF / Revenue | -2.4% | — |
| Capex IntensityCapex / Revenue | 3.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $16.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $980.0K | $43.7M | ||
| Q3 25 | $10.6M | $60.8M | ||
| Q2 25 | $13.6M | $12.0M | ||
| Q1 25 | $401.0K | $35.5M | ||
| Q4 24 | $12.4M | $33.1M | ||
| Q3 24 | $5.6M | $53.9M | ||
| Q2 24 | $11.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-2.2M | $43.5M | ||
| Q3 25 | $7.6M | $57.0M | ||
| Q2 25 | $11.9M | $9.3M | ||
| Q1 25 | $-424.0K | $26.9M | ||
| Q4 24 | $11.6M | $31.0M | ||
| Q3 24 | $4.5M | $49.8M | ||
| Q2 24 | $10.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -2.4% | 22.1% | ||
| Q3 25 | 8.8% | 31.7% | ||
| Q2 25 | 14.1% | 5.1% | ||
| Q1 25 | -0.5% | 15.9% | ||
| Q4 24 | 13.3% | 16.6% | ||
| Q3 24 | 5.4% | 29.6% | ||
| Q2 24 | 13.0% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.5% | 0.1% | ||
| Q3 25 | 3.4% | 2.2% | ||
| Q2 25 | 2.0% | 1.5% | ||
| Q1 25 | 1.0% | 5.1% | ||
| Q4 24 | 0.9% | 1.1% | ||
| Q3 24 | 1.3% | 2.4% | ||
| Q2 24 | 1.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMRC
| Subscription And Circulation | $65.2M | 73% |
| Partner And Services | $24.4M | 27% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
